Mostrar el registro sencillo del ítem
dc.contributor.author | Grille Montauban, Sofía | |
dc.contributor.author | Hernandez-Perez, Carlos | |
dc.contributor.author | Velloso, Elvira | |
dc.contributor.author | Novoa, Viviana | |
dc.contributor.author | Lorand-Metze, Irene | |
dc.contributor.author | Gonzalez, Jaqueline | |
dc.contributor.author | Solari, Liliana | |
dc.contributor.author | Cismondi, Valeria | |
dc.contributor.author | Serrano, Juan Carlos | |
dc.contributor.author | Burgnini, Andreína | |
dc.contributor.author | Rabelo-Carrasco, Laura | |
dc.contributor.author | Bacal, Nydia | |
dc.contributor.author | Trias, Natalia | |
dc.contributor.author | Guevara, Romina | |
dc.contributor.author | Rico Vido, Joyce | |
dc.contributor.author | Crisp, Renee | |
dc.contributor.author | Enrico, Alicia | |
dc.contributor.author | Boada, Matilde | |
dc.contributor.author | Pereira Cunha, Fernanda | |
dc.contributor.author | Fanessi, Viviana | |
dc.contributor.author | Venegas, María Belén | |
dc.contributor.author | Issouribehere, Diego | |
dc.contributor.author | Novoa, Andrea | |
dc.contributor.author | Lens, Daniela | |
dc.date.accessioned | 2024-05-07T18:13:36Z | |
dc.date.available | 2024-05-07T18:13:36Z | |
dc.date.issued | 2019-08-05 | |
dc.identifier.other | https://doi.org/10.1111/ijlh.13047 | |
dc.identifier.uri | http://repositorio.hospitalelcruce.org/xmlui/handle/123456789/1437 | |
dc.description.abstract | INTRODUCTION: Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The "Ogata score" is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low-risk MDS. We aimed to study the feasibility and the utility of the "Ogata score" for the diagnosis of MDS among Latin America (LA) Laboratories. METHODS: This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. "Ogata score" was calculated. RESULTS: The sensitivity of "Ogata score" was 75.6% (95% CI, 66.8-81.3), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 95.6% (95% CI, 88.5-98.3), and NPV was 65.4% (95% CI, 49.1-71.9). In low/intermediate-1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2-78.2), specificity was 91.2% (CI-95%, 79.7-96.7), PPV was 94.2% (95% CI, 86.4-97.8), and NPV was 62.1% (95% CI, 53.0-78.7). In the group of patients "without MDS specific markers" (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI-95%, 55.8-76.0), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 92.3% (95% CI, 82.2-97.1), and NPV was 63.5% (95% CI, 51.9-73.5). CONCLUSIONS: The diagnostic power found in this study was similar to the reported by Della-Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results. | es_AR |
dc.language.iso | en_US | es_AR |
dc.relation.ispartofseries | Int J Lab Hematol;2019 Aug;41(4):536-541 | |
dc.subject | Citometría de Flujo | es_AR |
dc.subject | América Latina | es_AR |
dc.title | Flow cytometry "Ogata score" for the diagnosis of myelodysplastic syndromes in a real-life setting. A Latin American experience | es_AR |
dc.type | Article | es_AR |